Introduction
Introduction

The liver response to chronic injury is characterized by woundhealing processes including inflammation and excessive deposition of extracellular matrix which leads to fibrosis/cirrhosis [1], the strongest risk for the development of hepatocellular carcinoma (HCC). During these processes, chemokines, a family of chemotactic cytokines, have been shown to play a critical role in the recruitment of inflammatory cells from blood stream and also in fibrogenesis
. Based on their conserved arrangement of the cysteine residues, chemokines are classified into four subfamilies C, CC, CXC and CX3C chemokines [4] . Fractalkine, also named CX3CL1, is the unique member of the CX3C class and exists in both soluble peptides and membrane-anchored forms. Thus, the chemokine domain is linked to a mucin-rich, transmembrane stalk and allows CX3CL1 to function as an adhesion molecule [5] whereas the proteolytic release of chemokine domain generate soluble chemoattractive molecule [6, 7] . CX3CL1 binds to the unique CX3CR1 receptor, a cell surface marker for NK cells, T cells, monocytes [8] which is also expressed by smooth muscle cells [9] . The importance of CX3CL1-CX3CR1 pathway during liver injuries has been suggested by the up-regulation of CX3CL1 and its receptor in acute and chronic liver diseases involving both inflammatory and epithelial cells [10, 11] . More recently, the potential modulation of host immune response by CX3CL1 and its receptor has been associated with improved survival of liver tumour-bearing mouse [12] and better prognosis in patients with HCC [13] . CX3CR1 [14] . Shedding of CX3CL1 has been attributed to ADAM10 and ADAM17 (tumour necrosis factor-␣-converting enzyme) activities through constitutive and induced pathways, respectively [6, 7, 15] .
Increases in matrix metalloproteinase activities were previously reported during liver injury and we demonstrated that extracellular matrix remodelling was associated with fibrosis progression [16] . As main source of matrix and proteases, the role of the profibrogenic hepatic stellate cells (HSCs) in this process has been well documented [17] . More recently, increased expression of members of ADAM family, including ADAM9, ADAM12 and ADAM17 was reported in patients with chronic liver diseases and expressed by the activated HSC [18] [19] [20] [21] 
Material and methods
Sample tissue
Relative quantification of mRNA by real-time PCR
Real-time quantitative PCR was performed as previously described [20] 
Zymography
Zymographic analyses were performed on conditioned medium from HSC culture as previously described [24] . Fig. 2A) . The increase in CX3CL1 expression was associated with release of soluble CX3CL1 in the HSC supernatant suggesting constitutive proteolysis of the mature CX3CL1 forms (Fig. 2B) . ADAM10 has been previously involved in the constitutive cleavage of CX3CL1 [15] whereas ADAM17 mediated the PMA inducible shedding of CX3CL1 [6, 7] . We showed that cultured human HSC expressed both ADAM10 and ADAM17 (Fig. 1B) 
Statistical analysis
IFN-␥ stimulation induces CX3CL1 expression in HSCs
cells by arrows. Specific antibodies were omitted and replaced by IgG isotype antibodies in negative control serial sections (e) and immunoperoxidase was counterstained with haematoxylin. (Original magnification: [a, b], 100; [c-f, g], 25; [h-l], 800). hydroxamate GW280264X only partially inhibited the release of soluble CX3CL1 from IFN-␥ stimulated cells in presence of PMA, suggesting that other proteases are implicated (supplementary data S2). In absence of PMA, the low amount of constitutive shedding of CX3CL1 did not permit to show significant difference between the two inhibitors. Because HSC is the major cellular source of MMP-2 in injured liver and its activity is inducible by PMA [25], we suggested that MMP-2 was potentially involved in CX3CL1 shedding. IFN-␥-treated HSC that secrete latent MMP-2 form were stimulated by the most widely studied inducer of MMP-2 activation, ConA. Treatment with ConA induced an increase in soluble CX3CL1 release and this effect was inhibited by adding batimastat whereas GW280264X only induced partial inhibition (Fig. 3A). Accordingly, CX3CL1 shedding was associated with the activation of MMP-2 as demonstrated by using zymography analysis. Under experimental condition, IFN-␥ treatment did not modify MMP-2 expression in cultured HSC (supplementary data S1). We further tested the ability of the natural metalloproteinase inhibitors TIMP1, TIMP2 and TIMP3 to block CX3CL1 cleavage in ConA-treated HSC (Fig. 3B). As demonstrated by analyses of the conditioned media using ELISA, TIMP2 and TIMP3 blocked specifically the release of CX3CL1 from HSC. TIMP1, however, did not block the generation of soluble CX3CL1. Both TIMP1 and TIMP2
have been shown to inhibit numerous MMPs; however TIMP1 has no effect on MMP-14, the main activator of MMP-2 and blocks ADAM10 [26] . (Fig. 3C) . Taken together our data suggested that activated MMP-2 from HSC might modulate the activity of CX3CL1 during chronic liver injury. [27] . The involvement of 
In contrast, TIMP3 have been reported to inhibit numerous ADAM members including ADAM12-17-19-10, ADAMTS 4-5 and only two gelatinases MMP-2 and MMP-9. Our data suggested that MMP-2 might cleave CX3CL1 from IFN-␥ stimulated human HSC. To further confirm the potential implication of MMP-2 in CX3CL1 processing, we investigated the release of soluble CX3CL1 in conditioned media from CHO cells co-transfected with MMP-2 and CX3CL1 expression vectors. The expression of the constitutive active MMP-2 (⌬ppMMP-2) led to the disappearance of mature CX3CL1 forms in cells whereas the inactive-mutant MMP-2 (pp E375A MMP-2) did not
Biological activity of CX3CL1 derived from HSCs
To evaluate the functional role of the soluble CX3CL1 forms derived from HSC, we investigated the potential of conditioned media from IFN-␥ stimulated HSC to induce ERK-dependent signalling pathway in HEK293T cells
Fig. 2 Effect of IFN-␥ on CX3CL1 expression in human hepatic stellate cells (HSCs
bottom panel). (D) Immunolocalization of CX3CL1 in human HSC unstimulated (a, e) or stimulated (b, c, f, g) with IFN-␥ in absence (a, b, e, f) or presence (c, g) of batimastat. Cells were permabilized (a-c) or unpermeabilized (e-g). Controls included incubation with IgG isotypes (d) and localization of ␣-SMA proteins (h).
Representative data from three independent experiments are shown. [15] and ADAM17 [6, 7] in constitutive and PMA-inducible shedding of CX3CL1, respectively. In the liver, the expression and distribution of MMP have been extensively studied [29] ; however, very few information are available on the members of ADAM family. We previously reported the increased expression of ADAM9 and ADAM12 in patients with HCC [20] and ADAM17 expression was associated with tumour differentiation [18] . More recently up-regulation of ADAM8-9-12 and -28 was also reported in chronic liver diseases [21] . In the present study, we investigated the expression of both ADAM10 and ADAM17 and the CX3CR1/CX3CL1 system in chronic liver diseases. According to previous report, the CX3CL1 and CX3CR1 mRNA levels were increased in injured livers [10, 11, 13] [28, 31, 40] 
CX3CL1/CX3CR1 pathway was further validated by using either blocking antibodies against CX3CR1 or CX3CR1-overexpressing HEK293T cell line (Fig. 4A). As positive control, treatment of the cells with recombinant CX3CL1 induced activation of extracellular signal-regulated kinase (ERK)1/2 suggesting that these cells responded to CX3CL1-mediated signalling pathway. The conditioned media from IFN-␥-stimulated HSC induced the activation of ERK1/2 in 293T cells. When HSC were co-stimulated by ConA, conditioned media enhanced ERK1/2 activation in wild-type 293T cells and induced an increase in CX3CR1 overexpressing 293T cells. In contrast, the ERK1/2 activation was totally inhibited by incubation of cells with blocking anti-CX3CR1 antibodies in both conditions. In order to demonstrate the implication of MMP-2 in the CX3CR1
